PMC:7102662 / 14736-18861
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T39 | 1464-1472 | Body_part | denotes | troponin | http://purl.org/sig/ont/fma/fma62338 |
| T40 | 1873-1882 | Body_part | denotes | troponins | http://purl.org/sig/ont/fma/fma62338 |
| T41 | 2638-2645 | Body_part | denotes | tissues | http://purl.org/sig/ont/fma/fma9637 |
| T42 | 2660-2674 | Body_part | denotes | cardiomyocytes | http://purl.org/sig/ont/fma/fma14067 |
| T43 | 2737-2742 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T144 | 92-100 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T145 | 201-209 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T146 | 459-467 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T147 | 762-770 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T148 | 921-929 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T149 | 1310-1318 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T150 | 1740-1749 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T151 | 2069-2077 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T152 | 2362-2370 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T153 | 2388-2430 | Disease | denotes | ST-segment elevation myocardial infarction | http://purl.obolibrary.org/obo/MONDO_0041656 |
| T154 | 2409-2430 | Disease | denotes | myocardial infarction | http://purl.obolibrary.org/obo/MONDO_0005068 |
| T155 | 2541-2544 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
| T156 | 2565-2573 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T157 | 2687-2695 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T158 | 2796-2804 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T159 | 2901-2904 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
| T160 | 3189-3192 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
| T161 | 3235-3243 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T162 | 3397-3412 | Disease | denotes | viral infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
| T163 | 3403-3412 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T95 | 230-231 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T96 | 556-566 | http://purl.obolibrary.org/obo/CLO_0002807 | denotes | in donning |
| T97 | 1444-1449 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
| T98 | 1786-1789 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T99 | 1899-1907 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | peptides |
| T100 | 2120-2123 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T101 | 2136-2137 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T102 | 2388-2390 | http://purl.obolibrary.org/obo/CLO_0009141 | denotes | ST |
| T103 | 2388-2390 | http://purl.obolibrary.org/obo/CLO_0050980 | denotes | ST |
| T104 | 2441-2444 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T105 | 2450-2451 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T106 | 2660-2674 | http://purl.obolibrary.org/obo/CL_0000746 | denotes | cardiomyocytes |
| T107 | 2731-2742 | http://purl.obolibrary.org/obo/CLO_0053065 | denotes | human cells |
| T108 | 2753-2754 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T22 | 1899-1907 | Chemical | denotes | peptides | http://purl.obolibrary.org/obo/CHEBI_16670 |
| T23 | 2388-2390 | Chemical | denotes | ST | http://purl.obolibrary.org/obo/CHEBI_141393 |
| T24 | 2484-2498 | Chemical | denotes | ACE inhibitors | http://purl.obolibrary.org/obo/CHEBI_35457 |
| T25 | 2488-2498 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T26 | 2500-2504 | Chemical | denotes | ACEi | http://purl.obolibrary.org/obo/CHEBI_35457 |
| T27 | 2510-2521 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
| T28 | 2896-2900 | Chemical | denotes | ACEi | http://purl.obolibrary.org/obo/CHEBI_35457 |
| T29 | 3184-3188 | Chemical | denotes | ACEi | http://purl.obolibrary.org/obo/CHEBI_35457 |
| T30 | 3452-3457 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T31 | 3501-3506 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T32 | 3591-3602 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T33 | 3603-3621 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T34 | 3626-3638 | Chemical | denotes | azathioprine | http://purl.obolibrary.org/obo/CHEBI_2948 |
| T35 | 3739-3744 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T36 | 3897-3908 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T37 | 3909-3927 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T38 | 4082-4086 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T45 | 2388-2408 | Phenotype | denotes | ST-segment elevation | http://purl.obolibrary.org/obo/HP_0012251 |
| T46 | 2409-2430 | Phenotype | denotes | myocardial infarction | http://purl.obolibrary.org/obo/HP_0001658 |
| T47 | 3758-3777 | Phenotype | denotes | prolong QT interval | http://purl.obolibrary.org/obo/HP_0001657 |
| T48 | 4105-4124 | Phenotype | denotes | prolong QT interval | http://purl.obolibrary.org/obo/HP_0001657 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T22 | 2332-2344 | http://purl.obolibrary.org/obo/GO_0042730 | denotes | fibrinolysis |
| T23 | 3397-3412 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | viral infection |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T121 | 0-28 | Sentence | denotes | 2.3 Management implications |
| T122 | 29-210 | Sentence | denotes | The overall management principles for patients presenting with COVID-19 who develop CV complications or who have pre-existing CVD are same as for any other patient without COVID-19. |
| T123 | 211-279 | Sentence | denotes | However, there are a few important points that need consideration-1. |
| T124 | 280-400 | Sentence | denotes | As caregivers, it is our utmost responsibility to protect ourselves from getting infected while managing these patients. |
| T125 | 401-525 | Sentence | denotes | Therefore, all heathcare personnel engaged in the care of COVID-19 patients must observe necessary precautions at all times. |
| T126 | 526-676 | Sentence | denotes | All of them should be trained in donning, usage, and doffing of the personal protective equipment in accordance with the existing practice guidelines. |
| T127 | 677-679 | Sentence | denotes | 2. |
| T128 | 680-840 | Sentence | denotes | The hospital systems need to ensure preparedness for dealing with large volume of COVID-19 patients, many of whom would need ICU care and/or acute cardiac care. |
| T129 | 841-1000 | Sentence | denotes | Appropriate protocols for rapid diagnosis, triage, isolation, and management of COVID-19 patients with CV complications should be developed and well-rehearsed. |
| T130 | 1001-1169 | Sentence | denotes | Rapid triaging and management of these patients is crucial, not only to allow efficient utilization of healthcare resources but also to minimize exposure to caregivers. |
| T131 | 1170-1324 | Sentence | denotes | There are already reports highlighting delays in delivering acute cardiac care due to extra precautions that need to be observed in view of COVID-19 [14]. |
| T132 | 1325-1372 | Sentence | denotes | Efforts should be made to minimize such delays. |
| T133 | 1373-1375 | Sentence | denotes | 3. |
| T134 | 1376-1516 | Sentence | denotes | Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. |
| T135 | 1517-1750 | Sentence | denotes | This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. |
| T136 | 1751-1913 | Sentence | denotes | The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. |
| T137 | 1914-2078 | Sentence | denotes | It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. |
| T138 | 2079-2216 | Sentence | denotes | The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]. |
| T139 | 2217-2219 | Sentence | denotes | 4. |
| T140 | 2220-2431 | Sentence | denotes | The individual hospitals may also have to reconsider risk-benefit ratio of primary percutaneous intervention vs fibrinolysis in patients with COVID-19 who present with ST-segment elevation myocardial infarction. |
| T141 | 2432-2434 | Sentence | denotes | 5. |
| T142 | 2435-2583 | Sentence | denotes | There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. |
| T143 | 2584-2680 | Sentence | denotes | These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. |
| T144 | 2681-2905 | Sentence | denotes | Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. |
| T145 | 2906-2996 | Sentence | denotes | However, to date, no experimental or clinical data have emerged to support these concerns. |
| T146 | 2997-3073 | Sentence | denotes | At the same time, the risks of discontinuing these therapies are well known. |
| T147 | 3074-3252 | Sentence | denotes | Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]. |
| T148 | 3253-3255 | Sentence | denotes | 6. |
| T149 | 3256-3413 | Sentence | denotes | Clinicians caring for these patients also need to be fully aware of the potential CV side-effects of various therapies used for treating the viral infection. |
| T150 | 3414-3575 | Sentence | denotes | Additionally, various anti-retroviral drugs have significant interactions with cardiac drugs, which need to be considered and appropriate dose modification done. |
| T151 | 3576-3727 | Sentence | denotes | More recently, chloroquine/hydroxychloroquine and azathioprine have been proposed as potential therapeutic options, based on preliminary evidence [20]. |
| T152 | 3728-3842 | Sentence | denotes | Both these drugs are known to prolong QT interval and due caution must be exercised when prescribing these agents. |
| T153 | 3843-4125 | Sentence | denotes | Their combination is best avoided and even when using chloroquine/hydroxychloroquine alone, daily electrocardiogram for monitoring QT interval is warranted, esp. in patients with hepatic or renal dysfunction and in those receiving another drug with potential to prolong QT interval. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T258 | 92-100 | SP_7 | denotes | COVID-19 |
| T259 | 201-209 | SP_7 | denotes | COVID-19 |
| T260 | 459-467 | SP_7 | denotes | COVID-19 |
| T261 | 762-770 | SP_7 | denotes | COVID-19 |
| T262 | 827-834 | UBERON:0000948 | denotes | cardiac |
| T263 | 921-929 | SP_7 | denotes | COVID-19 |
| T264 | 1219-1229 | GO:0007567 | denotes | delivering |
| T265 | 1236-1243 | UBERON:0000948 | denotes | cardiac |
| T266 | 1310-1318 | SP_7 | denotes | COVID-19 |
| T267 | 1456-1463 | UBERON:0000948 | denotes | cardiac |
| T268 | 1775-1785 | UBERON:0000948 | denotes | Cardiology |
| T269 | 1846-1853 | UBERON:0000948 | denotes | cardiac |
| T270 | 2069-2077 | SP_7 | denotes | COVID-19 |
| T271 | 2332-2344 | GO:0042730 | denotes | fibrinolysis |
| T272 | 2362-2370 | SP_7 | denotes | COVID-19 |
| T273 | 2409-2419 | UBERON:0002349 | denotes | myocardial |
| T274 | 2488-2498 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
| T275 | 2522-2539 | CHEBI:48561;CHEBI:48561 | denotes | receptor blockers |
| T276 | 2565-2573 | SP_7 | denotes | COVID-19 |
| T277 | 2608-2618 | GO:0010467 | denotes | expression |
| T278 | 2622-2626 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
| T279 | 2638-2645 | UBERON:0000479 | denotes | tissues |
| T280 | 2660-2674 | CL:0000746 | denotes | cardiomyocytes |
| T281 | 2687-2697 | SP_7 | denotes | SARS-CoV-2 |
| T282 | 2707-2711 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
| T283 | 2731-2736 | SP_6;NCBITaxon:9606 | denotes | human |
| T284 | 2796-2804 | SP_7 | denotes | COVID-19 |
| T285 | 3235-3243 | SP_7 | denotes | COVID-19 |
| T286 | 3397-3402 | NCBITaxon:10239 | denotes | viral |
| T287 | 3436-3441 | CHEBI:67079;CHEBI:67079 | denotes | anti- |
| T288 | 3441-3451 | NCBITaxon:11632 | denotes | retroviral |
| T289 | 3452-3457 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T290 | 3493-3500 | UBERON:0000948 | denotes | cardiac |
| T291 | 3501-3506 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T292 | 3591-3602 | CHEBI:3638;DG_10;CHEBI:3638 | denotes | chloroquine |
| T293 | 3603-3621 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
| T294 | 3626-3638 | CHEBI:2948;CHEBI:2948 | denotes | azathioprine |
| T295 | 3739-3744 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T296 | 3835-3841 | CHEBI:23888;CHEBI:23888 | denotes | agents |
| T297 | 3897-3908 | CHEBI:3638;DG_10;CHEBI:3638 | denotes | chloroquine |
| T298 | 3909-3927 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
| T299 | 4022-4029 | UBERON:0002107 | denotes | hepatic |
| T300 | 4033-4038 | UBERON:0002113 | denotes | renal |
| T301 | 4082-4086 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T44699 | 241-246 | UBERON:0000948 | denotes | tant |
| T13321 | 271-278 | UBERON:0000948 | denotes | ation-1 |
| T1958 | 337-341 | GO:0016265 | denotes | our |
| T10093 | 416-422 | GO:0016265 | denotes | heathc |
| T26141 | 586-600 | UBERON:0004535 | denotes | of the person |
| T57516 | 619-627 | SP_7 | denotes | ment in |
| T16826 | 640-651 | UBERON:0002349 | denotes | th the exis |
| T31833 | 665-675 | UBERON:0002349 | denotes | guidelines |
| T58582 | 734-742 | SP_7 | denotes | ealing w |
| T94661 | 814-824 | UBERON:0002349 | denotes | and/or acu |
| T87705 | 851-858 | UBERON:0000948 | denotes | e proto |
| T48656 | 987-994 | UBERON:0000948 | denotes | ll-rehe |
| T7641 | 1134-1141 | UBERON:0000948 | denotes | to mini |
| T19884 | 1351-1358 | UBERON:0000948 | denotes | minimiz |
| T28710 | 1450-1455 | GO:0016265 | denotes | (e.g. |
| T28698 | 1571-1578 | UBERON:0000948 | denotes | agnosti |
| T59720 | 1673-1681 | SP_7 | denotes | and woul |
| T39589 | 2005-2012 | UBERON:0000948 | denotes | ctually |
| T43336 | 2032-2039 | UBERON:0000948 | denotes | the ma |
| T74507 | 2067-2075 | SP_7 | denotes | h COVID- |
| T87124 | 2169-2177 | UBERON:0001621 | denotes | use of e |
| T70670 | 2179-2189 | UBERON:0002349 | denotes | ocardiogra |
| T13529 | 2204-2209 | NCBITaxon:10239 | denotes | tient |
| T86273 | 2384-2388 | GO:0016265 | denotes | ith |
| T62094 | 2396-2400 | SP_10 | denotes | nt e |
| T86471 | 2420-2424 | SP_10 | denotes | infa |
| T29868 | 2459-2464 | NCBITaxon:10239 | denotes | rega |
| T44693 | 2516-2521 | SP_6;NCBITaxon:9606 | denotes | ensin |
| T30153 | 2522-2527 | UBERON:0000948 | denotes | recep |
| T84285 | 2567-2577 | UBERON:0002349 | denotes | VID-19 pan |
| T53976 | 2592-2597 | NCBITaxon:10239 | denotes | ents |
| T87440 | 2660-2670 | UBERON:0002349 | denotes | cardiomyoc |
| T16635 | 2685-2693 | SP_7 | denotes | e SARS-C |
| T1147 | 2749-2765 | UBERON:0002084 | denotes | is a potentiall |
| T55144 | 2795-2811 | UBERON:0002084 | denotes | COVID-19 or dev |
| T79081 | 2916-2921 | UBERON:0000948 | denotes | o dat |
| T98834 | 2933-2941 | SP_7 | denotes | mental o |
| T81730 | 2956-2961 | UBERON:0000948 | denotes | have |
| T81536 | 3023-3027 | GO:0016265 | denotes | s of |
| T85605 | 3170-3178 | SP_7 | denotes | lly-indi |
| T35536 | 3256-3264 | SP_7 | denotes | Clinicia |
| T14057 | 3518-3526 | SP_7 | denotes | to be c |
| T37740 | 3681-3689 | CHEBI:33695;CHEBI:33695;SO:0000673 | denotes | c option |
| T78714 | 3736-3740 | SP_10 | denotes | se d |
| T37413 | 3752-3760 | SP_10 | denotes | wn to pr |
| T33567 | 3804-3814 | SP_7 | denotes | ercised wh |
| T76508 | 3875-3879 | SP_10 | denotes | d an |
| T48944 | 3919-3923 | CHEBI:18059;CHEBI:18059;GO:0006629 | denotes | oroq |
| T57411 | 3924-3932 | GO:0006629 | denotes | ine alon |
| T94539 | 4005-4012 | CHEBI:17234;CHEBI:17234;GO:0006006 | denotes | in pati |
| T59989 | 4013-4021 | GO:0006006 | denotes | nts with |
| T68492 | 47-58 | CHEBI:3638;DG_10;CHEBI:3638 | denotes | ment princi |
| T72351 | 59-77 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | les for patients p |
| T96108 | 173-180 | UBERON:0002107 | denotes | r any o |
| T69138 | 184-189 | UBERON:0002113 | denotes | pati |
| T30274 | 233-237 | CHEBI:23888;CHEBI:23888 | denotes | ew i |
| T302 | 459-467 | SP_7 | denotes | COVID-19 |
| T303 | 762-770 | SP_7 | denotes | COVID-19 |
| T304 | 827-834 | UBERON:0000948 | denotes | cardiac |
| T305 | 921-929 | SP_7 | denotes | COVID-19 |
| T306 | 1219-1229 | GO:0007567 | denotes | delivering |
| T307 | 1236-1243 | UBERON:0000948 | denotes | cardiac |
| T308 | 1310-1318 | SP_7 | denotes | COVID-19 |
| T309 | 1456-1463 | UBERON:0000948 | denotes | cardiac |
| T310 | 1775-1785 | UBERON:0000948 | denotes | Cardiology |
| T311 | 1846-1853 | UBERON:0000948 | denotes | cardiac |
| T312 | 2069-2077 | SP_7 | denotes | COVID-19 |
| T313 | 2332-2344 | GO:0042730 | denotes | fibrinolysis |
| T314 | 2362-2370 | SP_7 | denotes | COVID-19 |
| T315 | 2409-2419 | UBERON:0002349 | denotes | myocardial |
| T316 | 2488-2498 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
| T317 | 2522-2539 | CHEBI:48561;CHEBI:48561 | denotes | receptor blockers |
| T318 | 2565-2573 | SP_7 | denotes | COVID-19 |
| T319 | 2608-2618 | GO:0010467 | denotes | expression |
| T320 | 2622-2626 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
| T321 | 2638-2645 | UBERON:0000479 | denotes | tissues |
| T322 | 2660-2674 | CL:0000746 | denotes | cardiomyocytes |
| T323 | 2687-2697 | SP_7 | denotes | SARS-CoV-2 |
| T324 | 2707-2711 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
| T325 | 2731-2736 | SP_6;NCBITaxon:9606 | denotes | human |
| T326 | 2796-2804 | SP_7 | denotes | COVID-19 |
| T327 | 3235-3243 | SP_7 | denotes | COVID-19 |
| T328 | 3397-3402 | NCBITaxon:10239 | denotes | viral |
| T329 | 3436-3441 | CHEBI:67079;CHEBI:67079 | denotes | anti- |
| T330 | 3441-3451 | NCBITaxon:11632 | denotes | retroviral |
| T331 | 3452-3457 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T332 | 3493-3500 | UBERON:0000948 | denotes | cardiac |
| T333 | 3501-3506 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T334 | 3591-3602 | CHEBI:3638;DG_10;CHEBI:3638 | denotes | chloroquine |
| T335 | 3603-3621 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
| T336 | 3626-3638 | CHEBI:2948;CHEBI:2948 | denotes | azathioprine |
| T337 | 3739-3744 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
| T338 | 3835-3841 | CHEBI:23888;CHEBI:23888 | denotes | agents |
| T339 | 3897-3908 | CHEBI:3638;DG_10;CHEBI:3638 | denotes | chloroquine |
| T340 | 3909-3927 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
| T341 | 4022-4029 | UBERON:0002107 | denotes | hepatic |
| T342 | 4033-4038 | UBERON:0002113 | denotes | renal |
| T343 | 4082-4086 | CHEBI:23888;CHEBI:23888 | denotes | drug |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32247212-15897343-25241183 | 2676-2678 | 15897343 | denotes | 17 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 456 | 391-399 | Species | denotes | patients | Tax:9606 |
| 457 | 468-476 | Species | denotes | patients | Tax:9606 |
| 458 | 361-369 | Disease | denotes | infected | MESH:D007239 |
| 459 | 459-467 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 466 | 771-779 | Species | denotes | patients | Tax:9606 |
| 467 | 930-938 | Species | denotes | patients | Tax:9606 |
| 468 | 1040-1048 | Species | denotes | patients | Tax:9606 |
| 469 | 762-770 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 470 | 921-929 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 471 | 1310-1318 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 477 | 1507-1515 | Species | denotes | patients | Tax:9606 |
| 478 | 2055-2063 | Species | denotes | patients | Tax:9606 |
| 479 | 2202-2210 | Species | denotes | patients | Tax:9606 |
| 480 | 1740-1749 | Disease | denotes | infection | MESH:D007239 |
| 481 | 2069-2077 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 485 | 2348-2356 | Species | denotes | patients | Tax:9606 |
| 486 | 2362-2370 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 487 | 2409-2430 | Disease | denotes | myocardial infarction | MESH:D009203 |
| 498 | 2484-2487 | Gene | denotes | ACE | Gene:1636 |
| 499 | 2622-2626 | Gene | denotes | ACE2 | Gene:59272 |
| 500 | 2707-2711 | Gene | denotes | ACE2 | Gene:59272 |
| 501 | 2687-2697 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 502 | 2731-2736 | Species | denotes | human | Tax:9606 |
| 503 | 2842-2850 | Species | denotes | patients | Tax:9606 |
| 504 | 3218-3225 | Species | denotes | patient | Tax:9606 |
| 505 | 2565-2573 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 506 | 2796-2804 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 507 | 3235-3243 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 518 | 4000-4003 | Gene | denotes | esp | Gene:148713 |
| 519 | 3284-3292 | Species | denotes | patients | Tax:9606 |
| 520 | 4008-4016 | Species | denotes | patients | Tax:9606 |
| 521 | 3591-3602 | Chemical | denotes | chloroquine | MESH:D002738 |
| 522 | 3603-3621 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 523 | 3626-3638 | Chemical | denotes | azathioprine | MESH:D001379 |
| 524 | 3897-3908 | Chemical | denotes | chloroquine | MESH:D002738 |
| 525 | 3909-3927 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 526 | 3397-3412 | Disease | denotes | viral infection | MESH:D001102 |
| 527 | 4022-4050 | Disease | denotes | hepatic or renal dysfunction | MESH:D008107 |
| 533 | 67-75 | Species | denotes | patients | Tax:9606 |
| 534 | 185-192 | Species | denotes | patient | Tax:9606 |
| 535 | 92-100 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 536 | 155-158 | Disease | denotes | CVD | MESH:D002318 |
| 537 | 201-209 | Disease | denotes | COVID-19 | MESH:C000657245 |